Zacks Company Profile for Celularity, Inc. (CELU : NSDQ) |
|
|
|
Company Description |
Celularity Inc. is a clinical stage biotechnology company. It involved in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR and mesenchymal-like adherent stromal cells targeting indications across cancer, infectious and degenerative diseases. Celularity Inc., formerly known as GX Acquisition Corp., is based in NEW YORK.
Number of Employees: 123 |
|
|
|
Price / Volume Information |
Yesterday's Closing Price: $1.98 |
Daily Weekly Monthly
 |
20 Day Moving Average: 65,506 shares |
Shares Outstanding: 23.95 (millions) |
Market Capitalization: $47.42 (millions) |
Beta: 0.74 |
52 Week High: $5.22 |
52 Week Low: $1.00 |
Short Interest Ratio: |
|
% Price Change |
% Price Change Relative to S&P 500 |
4 Week |
3.12% |
-2.46% |
12 Week |
32.00% |
10.74% |
Year To Date |
-4.81% |
-10.84% |
|
|
|
|
|
|
|
General Corporate Information |
Officers
Robert J. Hariri - Chief Executive Officer and Chairman
David C. Beers - Chief Financial Officer
Dean C. Kehler - Director
Diane Parks - Director
Geoffrey Ling - Director
|
|
Peer Information
Celularity, Inc. (CORR.)
Celularity, Inc. (RSPI)
Celularity, Inc. (CGXP)
Celularity, Inc. (BGEN)
Celularity, Inc. (GTBP)
Celularity, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 151190204
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/24
Next Expected EPS Date: 11/06/25
|
|
Share - Related Items
Shares Outstanding: 23.95
Most Recent Split Date: 2.00 (0.10:1)
Beta: 0.74
Market Capitalization: $47.42 (millions)
|
|
|
|
|
|
EPS Information |
Dividend Information |
Analyst Coverage: No |
Dividend Yield: 0.00% |
Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
Current Fiscal Year EPS Consensus Estimate: $ |
Payout Ratio: |
Number of Estimates in the Fiscal Year Consensus: |
Change In Payout Ratio: |
Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
Next EPS Report Date: 11/06/25 |
|
|
|
|